Regeneron Pharmaceuticals, Inc. (REGN) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Regeneron (REGN) Q2 2026: Dupixent Drives 38% Growth, Pipeline Milestones Build Multi-Front Momentum
July 30, 2026
-
Regeneron (REGN) Q1 2026: Dupixent Drives 31% Growth, Pipeline Sets Up Multi-Blockbuster Visibility
June 17, 2026
-
Regeneron (REGN) Q3 2025: Dupixent Drives 26% Global Growth as Pipeline Delivers Six Pivotal Readouts
June 16, 2026
-
Regeneron (REGN) Q4 2025: Dupixent Profit Share Jumps 42% as Pipeline Readies 18 New Phase III Trials
June 15, 2026
-
Regeneron (REGN) Q2 2025: Dupixent Annualizes Above $17B, Pipeline Sets Stage for 10 Myeloma Trials
August 01, 2025
-
Regeneron (REGN) Q1 2025: ILEA U.S. Sales Plunge 39% as Copay Funding Gap Shifts Market Dynamics
July 01, 2025